Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 61

1.

A model for predicting individuals' absolute risk of esophageal adenocarcinoma: Moving toward tailored screening and prevention.

Xie SH, Lagergren J.

Int J Cancer. 2016 Jun 15;138(12):2813-9. doi: 10.1002/ijc.29988. Epub 2016 Jan 30.

2.

A model to determine absolute risk for esophageal adenocarcinoma.

Thrift AP, Kendall BJ, Pandeya N, Whiteman DC.

Clin Gastroenterol Hepatol. 2013 Feb;11(2):138-44.e2. doi: 10.1016/j.cgh.2012.10.026. Epub 2012 Oct 25.

PMID:
23103823
3.

Determining Risk of Barrett's Esophagus and Esophageal Adenocarcinoma Based on Epidemiologic Factors and Genetic Variants.

Dong J, Buas MF, Gharahkhani P, Kendall BJ, Onstad L, Zhao S, Anderson LA, Wu AH, Ye W, Bird NC, Bernstein L, Chow WH, Gammon MD, Liu G, Caldas C, Pharoah PD, Risch HA, Iyer PG, Reid BJ, Hardie LJ, Lagergren J, Shaheen NJ, Corley DA, Fitzgerald RC; Stomach and Oesophageal Cancer Study (SOCS) consortium, Whiteman DC, Vaughan TL, Thrift AP.

Gastroenterology. 2018 Apr;154(5):1273-1281.e3. doi: 10.1053/j.gastro.2017.12.003. Epub 2017 Dec 13.

PMID:
29247777
4.

Gastroesophageal reflux does not alter effects of body mass index on risk of esophageal adenocarcinoma.

Lagergren J, Mattsson F, Nyrén O.

Clin Gastroenterol Hepatol. 2014 Jan;12(1):45-51. doi: 10.1016/j.cgh.2013.07.027. Epub 2013 Aug 3.

PMID:
23920035
5.

Esophageal adenocarcinoma arising after antireflux surgery: a population-based analysis.

Kauttu TM, Rantanen TK, Sihvo EI, Räsänen JV, Puolakkainen P, Salo JA.

Eur J Cardiothorac Surg. 2011 Dec;40(6):1450-4; discussion 1454. doi: 10.1016/j.ejcts.2011.02.075. Epub 2011 May 4.

PMID:
21546258
6.

Predictors for neoplastic progression in patients with Barrett's Esophagus: a prospective cohort study.

Sikkema M, Looman CW, Steyerberg EW, Kerkhof M, Kastelein F, van Dekken H, van Vuuren AJ, Bode WA, van der Valk H, Ouwendijk RJ, Giard R, Lesterhuis W, Heinhuis R, Klinkenberg EC, Meijer GA, ter Borg F, Arends JW, Kolkman JJ, van Baarlen J, de Vries RA, Mulder AH, van Tilburg AJ, Offerhaus GJ, ten Kate FJ, Kusters JG, Kuipers EJ, Siersema PD.

Am J Gastroenterol. 2011 Jul;106(7):1231-8. doi: 10.1038/ajg.2011.153. Epub 2011 May 17.

PMID:
21577245
7.

Risk factors for esophageal adenocarcinoma after antireflux surgery.

Löfdahl HE, Lu Y, Lagergren P, Lagergren J.

Ann Surg. 2013 Apr;257(4):579-82. doi: 10.1097/SLA.0b013e3182888384.

PMID:
23426349
8.

Antireflux Surgery and Risk of Esophageal Adenocarcinoma: A Systematic Review and Meta-analysis.

Maret-Ouda J, Konings P, Lagergren J, Brusselaers N.

Ann Surg. 2016 Feb;263(2):251-7. doi: 10.1097/SLA.0000000000001438. Review.

PMID:
26501714
9.

Polymorphisms in MGMT and DNA repair genes and the risk of esophageal adenocarcinoma.

Doecke J, Zhao ZZ, Pandeya N, Sadeghi S, Stark M, Green AC, Hayward NK, Webb PM, Whiteman DC; Australian Cancer Study.

Int J Cancer. 2008 Jul 1;123(1):174-80. doi: 10.1002/ijc.23410.

10.
11.

Association between ambient ultraviolet radiation and risk of esophageal cancer.

Tran B, Lucas R, Kimlin M, Whiteman D, Neale R; Australian Cancer Study.

Am J Gastroenterol. 2012 Dec;107(12):1803-13. doi: 10.1038/ajg.2012.329. Epub 2012 Oct 2.

PMID:
23032986
12.

Model for Identifying Individuals at Risk for Esophageal Adenocarcinoma.

Kunzmann AT, Thrift AP, Cardwell CR, Lagergren J, Xie S, Johnston BT, Anderson LA, Busby J, McMenamin ÚC, Spence AD, Coleman HG.

Clin Gastroenterol Hepatol. 2018 Aug;16(8):1229-1236.e4. doi: 10.1016/j.cgh.2018.03.014. Epub 2018 Mar 17.

PMID:
29559360
13.

Recent developments in esophageal adenocarcinoma.

Lagergren J, Lagergren P.

CA Cancer J Clin. 2013 Jul-Aug;63(4):232-48. doi: 10.3322/caac.21185. Review.

14.

Venous Thrombosis Risk after Cast Immobilization of the Lower Extremity: Derivation and Validation of a Clinical Prediction Score, L-TRiP(cast), in Three Population-Based Case-Control Studies.

Nemeth B, van Adrichem RA, van Hylckama Vlieg A, Bucciarelli P, Martinelli I, Baglin T, Rosendaal FR, le Cessie S, Cannegieter SC.

PLoS Med. 2015 Nov 10;12(11):e1001899; discussion e1001899. doi: 10.1371/journal.pmed.1001899. eCollection 2015 Nov.

15.

Dietary antioxidant and mineral intake in humans is associated with reduced risk of esophageal adenocarcinoma but not reflux esophagitis or Barrett's esophagus.

Murphy SJ, Anderson LA, Ferguson HR, Johnston BT, Watson PR, McGuigan J, Comber H, Reynolds JV, Murray LJ, Cantwell MM.

J Nutr. 2010 Oct;140(10):1757-63. doi: 10.3945/jn.110.124362. Epub 2010 Aug 11.

PMID:
20702746
16.

Recent advances in oesophageal diseases.

Al Dulaimi D.

Gastroenterol Hepatol Bed Bench. 2014 Summer;7(3):186-9.

18.

Evaluation of a 4-protein serum biomarker panel-biglycan, annexin-A6, myeloperoxidase, and protein S100-A9 (B-AMP)-for the detection of esophageal adenocarcinoma.

Zaidi AH, Gopalakrishnan V, Kasi PM, Zeng X, Malhotra U, Balasubramanian J, Visweswaran S, Sun M, Flint MS, Davison JM, Hood BL, Conrads TP, Bergman JJ, Bigbee WL, Jobe BA.

Cancer. 2014 Dec 15;120(24):3902-13. doi: 10.1002/cncr.28963. Epub 2014 Aug 5.

19.

Opportunities for Preventing Esophageal Adenocarcinoma.

Maret-Ouda J, El-Serag HB, Lagergren J.

Cancer Prev Res (Phila). 2016 Nov;9(11):828-834. Epub 2016 Sep 13. Review.

20.

Clinical and endoscopic factors predict higher pathologic grades of Barrett dysplasia.

Anandasabapathy S, Jhamb J, Davila M, Wei C, Morris J, Bresalier R.

Cancer. 2007 Feb 15;109(4):668-74.

Supplemental Content

Support Center